Xilis is a biotech company developing next-generation technologies to guide precision therapy for cancer patients and accelerate drug discovery and development.

Xilis' platform guides treatment decisions for oncologists to improve cancer care outcomes for patients and supports drug discovery and development for pharmaceutical companies.

Xilis was founded in 2019 by Xiling Shen, David Hsu, and Hans Clevers. The company is headquartered in Durham, North Carolina, with an office in South San Francisco, CA.

 

Xilis’ proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution.

 

Xilis leverages MOS and AI-driven algorithms to develop its Precision Oncology Platform to accurately predict therapeutic responses to help clinicians prioritize cancer treatment strategies for each patient. Xilis is also developing a Xilis Response Score™ for the clinic, enabling oncologists to make informed and timely treatment decisions.

 

Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniature patient- derived tumors that capture the original heterogeneity and microenvironment for therapeutic profiling.

 

Xilis is backed by Mubadala Capital, GV, LSP, Felicis Ventures, Two Sigma Ventures, Pear VC, Catalio Capital Management, Alexandria Venture Investments, FPV Ventures, and others. The company closed an extension of $19M to its Series A round on Jul 13, 2022, bringing the round total to $89M. The additional investment brings Xilis' total funding to $92M to date.

 

 

  • Year founded: 2019
  • Funding Info: $92M over 3 Rounds (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Durham
  • State: North Carolina
  • Country: United States
Related businesses